• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

piers.blombery@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-9902-0022

A/Prof Piers Blombery

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

289 Scholarly works
10 Projects

HIGHLIGHTS

  • 2024

    Research grants (ARC, NHMRC, MRFF)

    ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
  • 2023

    Journal article

    Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
    DOI: 10.1182/blood.2022016090
  • 2022

    Journal article

    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
    DOI: 10.1182/blood.2022016040
  • 2022

    Journal article

    Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
    DOI: 10.1182/bloodadvances.2022008325
  • 2022

    Journal article

    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    DOI: 10.1182/blood.2021012775
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Understanding and Averting Blood Cancer Resistance to Therapy
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Diagnosis, Discovery and Novel Phenotype Characterisation Using Multimodal Genomics in Patients With Inherited Bone Marrow Failure and Related Disorders
Piers Blombery

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia
    DOI: 10.1182/bloodadvances.2026020789
  • 2026

    Journal article

    Activating somatic EPOR mutation in primary erythrocytosis
    DOI: 10.1016/j.pathol.2026.04.005
  • 2026

    Journal article

    Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.
    DOI: 10.1111/bjh.70850
  • 2026

    Journal article

    MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.
    DOI: 10.1182/blood.2026034228
  • 2026

    Journal article

    CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.
    DOI: 10.1182/blood.2026033477
  • 2026

    Journal article

    A Case of Primary Cutaneous BRAFV600E Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA
    DOI: 10.1111/ajd.70143
  • 2026

    Journal article

    Novel chimeric PD-L1::PD-L2 fusion and immune evasion in lymphoma
    DOI: 10.1038/s41698-026-01654-0
  • 2026

    Journal article

    A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.
    DOI: 10.1182/blood.2026034942

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224